Bio-Rad Bundles FCS Express Flow Cytometry Analysis Software with the ZE5 Cell Analyzer
HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today that its ZE5 Cell Analyzer now comes with FCS Express flow cytometry analysis software from De Novo Software. By providing FCS Express with the ZE5 Cell Analyzer, Bio-Rad extends the analytical capabilities of the instrument, providing users a complete flow cytometry workflow solution.
Researchers using the ZE5 Cell Analyzer with FCS Express can rapidly acquire and analyze high parameter data and produce presentation-ready results as well as publication-quality graphics. The addition of FCS Express offers high dimensional analysis tools including tSNE, SPADE, and cluster analysis to ZE5 Cell Analyzer customers at install.
"The ZE5 Cell Analyzer is a powerful and flexible high-parameter instrument and FCS Express matches this power and flexibility,” said Greg Fisher, Director of Cell Biology, Bio-Rad. “With the partnership, Bio-Rad leverages De Novo Software’s extensive expertise in flow cytometry data analysis and provides our customers an end-to-end solution right out of the box," he added.
Bio-Rad is offering new ZE5 Cell Analyzer customers a renewable license of FCS Express for one year at no charge for non-commercial use. Existing ZE5 Cell Analyzer customers have the option to purchase a renewable FCS Express license from Bio-Rad.
About the ZE5 Cell Analyzer
The ZE5 Cell Analyzer combines high throughput with high-parameter capabilities in a flexible format that transitions from tubes to plates seamlessly. Offering up to five lasers and 30 detectors with event rates greater than 100,000 cells per second and the ability to detect small particles that are less than 0.2 µm, the ZE5 helps researchers glean more results in less time from their most precious samples, which is invaluable for understanding the complexity of biology and disease.
BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. All trademarks used herein including FCS EXPRESS are the property of their respective owners.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications